Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. Yamamoto Y, et al. Among authors: ohtani s. Breast Cancer. 2024 May;31(3):340-346. doi: 10.1007/s12282-024-01566-6. Epub 2024 Apr 3. Breast Cancer. 2024. PMID: 38570435 Free PMC article.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H, Yamamoto Y, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Ohtani S, Kashiwaba M, Taira N, Toyama T, Fujisawa T, Masuda N, Shibahara Y, Sasano H, Yamaguchi T. Iwata H, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2023 Jun;199(2):231-241. doi: 10.1007/s10549-023-06874-7. Epub 2023 Mar 22. Breast Cancer Res Treat. 2023. PMID: 36947277 Free PMC article. Clinical Trial.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. Among authors: ohtani s. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Masuyama M, et al. Among authors: ohtani s. Cancer Med. 2023 Sep;12(17):17718-17730. doi: 10.1002/cam4.6390. Epub 2023 Aug 1. Cancer Med. 2023. PMID: 37525895 Free PMC article.
The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.
Kawai M, Ohtani S, Iwasaki M, Yamamoto S, Takamatsu K, Okamura H, Arai M, Nomura T, Ozaki S, Shibata KI, Akabane A, Motoi F, Yamauchi C, Yamamoto Y, Iwata H, Saji S. Kawai M, et al. Among authors: ohtani s. Breast Cancer. 2024 Mar;31(2):166-178. doi: 10.1007/s12282-023-01531-9. Epub 2023 Dec 26. Breast Cancer. 2024. PMID: 38147174 Free PMC article.
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. Yamamoto Y, et al. Among authors: ohtani s. Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589-z. Online ahead of print. Breast Cancer. 2024. PMID: 38735003 No abstract available.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Kobayashi K, Masuda N, Mizuno T, Miura K, Tokuda Y, Yoshinami T, Kawaguchi H, Ohtani S, Saeki T, Toi M, Takeuchi M, Ito Y. Kobayashi K, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2023 Oct;201(3):409-415. doi: 10.1007/s10549-023-07030-x. Epub 2023 Jul 22. Breast Cancer Res Treat. 2023. PMID: 37480384 Clinical Trial.
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia JA, Zhou X, Haiderali A, Nguyen AM, Cortes J, Winer EP. Schmid P, et al. Among authors: ohtani s. Eur J Cancer. 2023 Dec;195:113393. doi: 10.1016/j.ejca.2023.113393. Epub 2023 Oct 21. Eur J Cancer. 2023. PMID: 37976633 Clinical Trial.
471 results